Abstract
In addition to its function in tissue pressure regulation, the lymphatic system is an important component of the immune system. Soluble antigens and antigen-presenting cells are transported via lymphatic vessels into lymphoid organs including the lymph nodes, tonsils, spleen and Peyer's patches, where immune responses are initiated. In addition, specialized lymphatic vessels, the lacteals, are involved in the absorption of dietary fat and fat soluble vitamins [1].

Tumour-induced lymphangiogenesis promotes metastasis
The lymphatic system gained much attention when tumour-associated lymphangiogenesis was correlated with metastasis to draining lymph nodes in several mouse models; in these models, tumours expressed the lymphangiogenic growth factors vascular endothelial growth factor (VEGF)-A, VEGF-C or VEGF-D [4-8]. Since then, VEGF-A, -C and -D have been detected in a range of human tumour types, such as melanoma and breast, cervical, non-small-cell lung, prostate, colorectal and gastric cancers. Furthermore, tumourassociated lymphatic vessel density was correlated with metastasis
to the draining lymph nodes, distant metastases and poor prognosis [9] [10] [11] [12] . These studies suggested that expression of lymphangiogenic growth factors by tumour cells induces lymphangiogenesis, which promotes metastasis (via lymphatic vessels) to draining lymph nodes and beyond. Furthermore, the initiation of lymphatic metastasis correlated with tumour lymphangiogenesis in a human lung cancer xenograft model in mice (Fig. 1) [13] .
In addition to increasing the number of lymphatic vessels, tumours also induce lymphatic vessel enlargement, which has been associated with increased passage of tumour cell clusters to sentinel lymph nodes in mouse and human tumours [13] [14] [15] [16] [17] [18] [19] . Lymphatic vessel enlargement is at least partly mediated by VEGF-C, produced by tumour cells, which was demonstrated in mouse models of melanoma and lung cancer xenografts [13, 20] .
In contrast to angiogenesis, lymphangiogenesis in tumours is likely to be almost exclusively due to the proliferation and sprouting of pre-existing vessels, rather than incorporation of circulating endothelial progenitor cells. In mice that were sub-lethally irradiated and then given grafts of green fluorescent protein (GFP)-expressing bone marrow cells, the GFP-expressing cells did not incorporate into the newly formed lymphatic vessels induced by Lewis lung carcinoma xenotransplants or by VEGF-C delivery [21]. However, studies in inflamed mouse corneas or those exposed to fibroblast growth factor-2 (FGF-2) and human kidney transplants indicate that a minor number of bone-marrow derived cells, proposed to be macrophages, might contribute to the growth of lymphatic vessels [22-24].
Tumour-induced lymph node lymphangiogenesis precedes cancer metastasis to lymph nodes
In mouse models of skin carcinogenesis in which VEGF-A or VEGF-C was overexpressed in the skin, lymphangiogenesis was found to occur not only at the tumour site but also in the tumourdraining lymph nodes and to correlate with metastasis to lymph nodes and beyond [7, 8] [67] and endothelin-1 (ET-1) [68] . Recently, transforming growth factor-␤1 (TGF-␤1) has been identified to be a negative regulator of lymphangiogenesis in wound healing [69] . The [78] [79] [80] , and by VEGF-C small interfering (si)RNA in a breast cancer model and in gastric cancer xenografts [81, 82] . Recently, an anti-neuropilin-2 antibody was shown to inhibit tumour-induced lymphangiogenesis in experimental mammary and brain tumour models and to delay metastasis to sentinel lymph nodes [83] . Neuropilin-2 is a cell-surface transmembrane protein expressed on tumourassociated but not normal lymphatic vessels [83] . It functions as a co-receptor for VEGF-C and VEGF-A [84] and is not required for developmental lymphangiogenesis [85] . [70] .
Peri-and intra-tumoral lymphangiogenesis
Inhibition of the VEGF-C/-D/VEGFR-3 pathway in adult mice did not affect normal lymphatic vessels [86] and was not reported to induce oedema formation, so this appears to be a relatively safe therapeutic strategy. However, although targeting the VEGF-C/ VEGF-D/VEGFR-3 axis efficiently blocks lymphangiogenesis and reduces metastasis to the lymph nodes, it does not completely inhibit formation of metastases in lymph nodes. Furthermore, longterm expression of VEGFR-3-IgG inhibited macrometastasis but not micrometastasis [13]. This indicates that complete blockage of lymphatic metastasis could require targeting of additional lymphangiogenic pathways and of the mechanism of lymphatic vessel invasion by tumour cells. Recently etodolac, an inhibitor of cyclooxygenase-2, inhibited lymphangiogenesis and lymph node metastasis in a mouse model of gastric cancer. Etodolac decreased VEGF-C and -D levels in tumour-associated macrophages, suggesting that reducing macrophage-mediated tumour lymphangiogenesis might help prevent lymph node metastasis
In models of inflammation and wound repair, several anti-lymphangiogenic strategies have been successful -these strategies might also be efficient in inhibiting tumour-induced lymphangiogenesis. A small molecule antagonist of the integrin subunit ␣5 inhibited inflammation-induced lymphangiogenesis in the mouse cornea [87] , antibodies to integrin subunits ␣1 or ␣2 blocked VEGF-induced lymphangiogenesis in mouse skin [88] , and a specific antagonist of the endothelin receptor type B decreased lymphangiogenesis in a matrigel plug assay in mice [68] . Moreover, siRNA knockdown of endothelial-specific molecule-1 blocked in vivo lymphangiogenesis in matrigel assays [54] and a recent study indicated that transforming growth factor (TGF)-␤1 inhibits lymphangiogenesis during wound repair [69] . Additional targets might be revealed by characterizing proteins that transcriptional and proteomic profiling studies showed were expressed on activated LEC [52] [53] [54] [55] .
The ability of anti-lymphangiogenic agents to prevent the early stages of metastasis has been established in animal models. 
However, the effect of anti-lymphangiogenic therapies on established
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Lymphatic invasion by tumour cells
Studies in human breast cancer revealed that tumour cell invasion into lymphatic vessels predicted lymph node involvement and was a prognostic factor for overall and disease-free survival [95, 96] . In accordance with these findings, lymphatic vessel invasion was found to be a prognostic indicator of lymph node metastasis in human melanoma [97] and of adverse outcome in several studies of gastric cancer [98] [99] [100] [101] and node-negative carcinomas of bladder and oesophagus [102, 103] . These findings indicate that quantification of tumour cell invasion of lymphatic vessels might be used in prognosis in cancer patients with uninvolved lymph nodes. [105, [110] [111] [112] [113] [107] . [124] . [126] . Interstitial administration of the contrast agent also enabled lymphangiography of larger and deep lymphatic vessels by MRI in mice and human beings [94, 127, 128] and, less successfully, by X-ray scans [94] . [94] . Tc-human serum albumin is administered, either intradermally or subcutaneously [129] [130] and subcutaneous IC-green injection revealed dilated lymphatic channels and lymph flow obstruction in human patients suffering from secondary lymphedema [131] . Furthermore, lymph flow has been quantified in breast cancer patients using IC-green [132] .
Lymphangiogenic growth factors
. A potential reason for this discrepancy could be the fact that serum levels of lymphangiogenic growth factors vary among patients. For instance, high levels of serum VEGF-C in patients with non-metastatic cancers are in the range of those of patients with metastatic tumours
Therefore, it is a challenge to interpret the levels of circulating VEGF-C for prognostic purposes without knowing each patient's pre-disease level. This issue probably also affects measurement of other lymphangiogenic factors. Furthermore, lymphangiogenic growth factors such as VEGF-C are produced during other conditions, such as inflammation [1], which could affect the reliability of this prognostic method. Lymphangiogenic growth factors have been quantified in tumour biopsy samples using RT-PCR and ELISA analyses. Increased expression of VEGF-C and VEGF-D mRNA and protein in tumour biopsies has been associated with lymph node metastasis [114-117]. However, to perform these analyses, biopsies need to be carefully collected, because intra-tumoral VEGF-C and VEGF-D levels were found to be lower than peri-tumoral levels [118-122]; biopsies derived from the tumour centre therefore might not represent VEGF-C or VEGF-D levels at the hot spots of lymphangiogenic activity. Lymphangiogenic growth factors can also be detected on tissue sections. This method has the advantage of preserving the histological environment and allows discrimination between intraand peri-tumoral structures and hot spots of lymphangiogenesis, as well as cell-type specific expression of lymphangiogenic growth factors [12].
Lymph node lymphangiogenesis
Interestingly, pre-metastatic lymphatic vessel expansion in tumour-draining lymph nodes was associated with increased lymph flow to the lymph nodes in a mouse model of metastatic melanoma [26]. Lymph flow imaging was performed in vivo using near infrared quantum dots or Cy5.5 labelled magnetic nanoparticles. An increased amount and rate of lymph flow through draining lymph nodes in the same mouse model was also shown by magnetic resonance imaging (MRI) after injection of a gadolinium-based contrast agent [123]. These experiments suggest that detecting increased lymph flow to sentinel lymph nodes, or increased lymph node volumes might predict metastasis to lymph nodes. Further studies on this subject are needed to confirm this hypothesis.
Diagnostic value of tumour-associated lymphangiogenesis
Although quantification of tumour-induced lymphangiogenesis is a valuable method for predicting lymph node metastasis, it is not clear whether detection of lymphangiogenesis might be used in the early detection of metastases in lymph nodes or elsewhere. Because lymphangiogenesis has been found in lymph nodes of several experimental cancer models, as well as in patients, it might be prognostic factor for metastasis, especially because it has been shown to precede cancer metastasis in mice [7, 8, 25, 26]. If premetastatic lymphangiogenesis is as well a feature in human cancer patients, it remains to be determined whether pre-metastatic and metastatic lymph node lymphangiogenesis can be used to develop reliable diagnostics. It may be a challenge, however, to distinguish between lymph node lymphangiogenesis evoked by cancer metastasis or by inflammation
Imaging of lymphatic vessels
Contrast agents can be delivered intravenously, via hyperpermeable blood vessels, through interstitial tissue, into the lymphatic vessels [94]. Particles up to several nanometres in size can extravasate from blood vessels and pool into lymphatic vessels through gap junctions between the endothelial cells. Particles up to 100 nm in diameter extravasate from the blood into the interstitial space, where they are phagocytosed by macrophages and are further transported to the lymph nodes. Particles larger than 100 nm typically remain trapped in the interstitial tissue
Imaging lymphatic drainage
. A scintigraphic camera that detects ␥ emission is used to visualize the radiotracer's flow pattern. More recently, indocyan green (IC-green), an albumin-binding near-infrared dye was investigated for assessing lymphatic function and lymphedema. Using IC-green, pulsative lymph flow has been shown in pigs
To identify tumour-draining lymph nodes in human cancer patients, Tc-99m-labelled sulphur colloid, albumin nanocolloid, antimony colloid or other soluble non-colloids are injected intradermally or subcutaneously around the tumour and their drainage to lymph nodes is detected by a ␥ scintigraphic camera [94] 
. A range of further radiographic contrast agents and dyes have been tested in experiments with mice and in clinical trials
to track sentinel lymph nodes of tumours [133] [134] [135] [136] [137] [138] [139] [138] , dendrimers [137] , magnetic nanoparticles [26] , indocyan green and different quantum dots [26, [134] [135] [136] [137] 139] were found in lymph nodes following injection into the interstitial tissue. Lymph flow to lymph nodes could also be tracked and quantified by MRI using a gadolinium-based contrast agent [123, 140] . [94] . However, ultrasound cannot image deep-lying lymph nodes [94] . Conflicting results have been published regarding the sensitivity and specificity of the combination of ultrasound and fine-needle aspiration biopsy in detection of tumour cells [141, 142] . One study reported that lymph nodes could be visualized by ultrasound upon interstitial injection of microbubbles [143] . Metastasis-induced enlargement of lymph nodes can also be imaged by computed tomography (CT) or MRI [94, 129] . In addition, positron emission tomography (PET) can be used after intravenous injection of 18 F-fluorodeoxyglucose for direct detection of metastases in lymph nodes [94, 129] . Often PET imaging is combined with CT or X-ray analyses to combine PET data with structural information [144] . CT, MRI and US are routinely used in clinical settings to evaluate lymph nodes. However, none of these methods is sensitive enough to detect micrometastases. Micrometastases, particularly those from breast tumours, are often found in normal-sized and normal-shaped lymph nodes [145, 146] . Furthermore, lymph node enlargement is not necessarily a result of malignancy but can also be caused by hyperplasia or infections [129] . [146, 147] . Further improvements in sensitivity might be achieved by the combination of different imaging modalities [129, 146] . Non-invasive imaging of lymph node lymphangiogenesis in tumour-draining lymph nodes could be more sensitive than current methods of detecting metastases. 
Non-invasive imaging of lymph node metastases
The removal of tumour-draining lymph nodes, in particular the complete dissection of auxiliary lymph node that is performed in breast cancer patients, can trigger serious adverse reactions, including lymphedema. Questions have been raised about the benefits of routinely performing auxiliary lymph node dissection [94]. Thus, non-invasive methods were developed to detect metastasis-containing lymph nodes and avoid the unnecessary dissection of metastases-free lymph nodes. Ultrasound (US) can detect changes in shape, size and echogenicity induced by metastases. Because ultrasound does not employ a contrast agent, it might be used to detect metastases in lymph nodes that obstruct the drainage of radiotracer to sentinel lymph nodes
Several attempts have been made to increase the sensitivity of metastasis detection. Whereas conventional MRI is able to detect nodal metastasis as small as 8-10 mm, MRI, after injection of lymphotropic monocrystalline iron oxide nanoparticles, detects nodal metastases as small as 2 mm
